MarketCap
Facebook
X
TelegramGeschäftsbericht 2026
hinzugefügt 14.05.2026
Aptorum Group Limited Anteile 2011-2026 | APM
Anteile Jährlich Aptorum Group Limited
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 7.35 M | 5.45 M | 4.52 M | 3.57 M | 3.5 M | 31.1 M | 29 M | 27.9 M | 27 M | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 31.1 M | 3.5 M | 15.5 M |
Anteile Vierteljährlich Aptorum Group Limited
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.35 M | 7.13 M | 7.13 M | 5.45 M | 5.34 M | 4.52 M | 3.85 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 7.35 M | 3.85 M | 5.82 M |
Anteile anderer Aktien in der Pharmaeinzelhändler
| Name | Anteile | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
38.7 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
4.73 M | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
10.2 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Coherus BioSciences
CHRS
|
117 M | $ 1.7 | 3.35 % | $ 199 M | USA |
 |
I-Mab
IMAB
|
220 M | - | - | $ 866 M | China |
 |
Celldex Therapeutics
CLDX
|
66.4 M | $ 31.61 | 2.46 % | $ 2.1 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
44.7 B | - | 2.54 % | $ 160 B | France |
 |
BioNTech SE
BNTX
|
242 M | $ 93.75 | 1.62 % | $ 22.7 B | Germany |
 |
AstraZeneca PLC
AZN
|
1.55 B | - | - | $ 96.9 B |  Britain |
 |
CRISPR Therapeutics AG
CRSP
|
89.9 M | $ 53.6 | 3.9 % | $ 4.82 B |  Schweiz |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
4.28 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
9.34 B | - | 0.74 % | $ 768 M |  Israel |
 |
Compugen Ltd.
CGEN
|
93.4 M | $ 2.68 | 0.94 % | $ 250 M | Israel |
 |
Abcam plc
ABCM
|
229 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
98.5 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
54.9 B | - | -18.52 % | $ 27.3 M | Britain |
|
Enlivex Therapeutics Ltd.
ENLV
|
45.7 M | $ 0.81 | 18.2 % | $ 37 M | Israel |
 |
Esperion Therapeutics
ESPR
|
208 M | $ 3.13 | 0.32 % | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
26.9 M | $ 31.59 | 0.94 % | $ 850 M | USA |
 |
Affimed N.V.
AFMD
|
120 M | - | -34.95 % | $ 21.5 M | Germany |
|
Forte Biosciences
FBRX
|
12.9 M | $ 21.99 | 0.23 % | $ 285 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
21.6 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
22.6 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
68.9 M | - | -7.31 % | $ 87 M | USA |
 |
Galectin Therapeutics
GALT
|
63.9 M | $ 2.69 | -3.71 % | $ 172 M | USA |
 |
Generation Bio Co.
GBIO
|
66.6 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
8.34 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
34.4 M | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
15.4 M | - | - | $ 7.46 M | Israel |
 |
Grifols, S.A.
GRFS
|
680 M | $ 8.02 | 0.06 % | $ 5.45 B |  Spain |
 |
Hutchison China MediTech Limited
HCM
|
858 M | $ 11.78 | 0.26 % | $ 10.1 B | China |
 |
Cyclacel Pharmaceuticals
CYCCP
|
2.19 M | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
59.3 M | - | - | $ 384 M | Britain |
 |
Heron Therapeutics
HRTX
|
167 M | $ 0.9 | 1.4 % | $ 150 M | USA |
 |
Gracell Biotechnologies
GRCL
|
338 M | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
14.3 M | $ 14.75 | -0.97 % | $ 212 M | USA |
 |
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
3.17 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
14.3 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.65 M | $ 3.31 | -3.88 % | $ 5.45 M | Israel |
 |
Aptose Biosciences
APTO
|
2.45 M | - | -45.71 % | $ 1.2 M | Canada |